Evidence map›Paper›PMID 36804919›Full record

ArticleJournal of medical case reports2023

Bilateral central retinal vein occlusion as an initial presentation of Waldenström macroglobulinemia: a case report.

Suraj Shrestha, Elisha Poddar, Bibhav Bashyal, Aayush Adhikari, Prabin Pathak, Suman Acharya, Surendra Sapkota, Anjan Bhattarai, Samriddha Raj Pant, Anjan Shrestha

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of medical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Suraj ShresthaMaharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal. multisurazz@gmail.com.ORCID http://orcid.org/0000-0001-6888-260X
Elisha PoddarMaharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal.
Bibhav BashyalDepartment of Internal Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
Aayush AdhikariMaharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal.
Prabin PathakDepartment of Pathology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
Suman AcharyaDepartment of Internal Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
Surendra SapkotaDepartment of Internal Medicine, Saint Agnes Hospital, Maryland, USA.
Anjan BhattaraiMaharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal.
Samriddha Raj PantMaharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal.
Anjan ShresthaDepartment of Pathology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
Tribhuvan University Teaching Hospital · NPSaint Agnes Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWaldenström macroglobulinemia is a rare hematological malignancy and is the most common diagnosis in patients with hyperviscosity syndrome. Bilateral central retinal vein occlusion as an initial presentation of hyperviscosity syndrome in Waldenström macroglobulinemia is rare. CASE PRESENTATION: A 42-year-old Nepalese male presented with sudden-onset bilateral painless blurring of vision. Fundus examination revealed bilateral, diffusely dilated, tortuous retinal veins and intraretinal deep blot hemorrhages in all four quadrants of the retina in both eyes; features of bilateral central retinal vein occlusion. Serum electrophoresis showed hypoalbuminemia with an immunoglobulin M kappa monoclonal spike. Bone marrow picture and immunohistochemistry analysis were suggestive of lymphoplasmacytic lymphoma. The patient received systemic therapy for Waldenström macroglobulinemia, along with intravitreal bevacizumab.

conclusionAdequate hydration, plasmapheresis, and a combination of bortezomib, dexamethasone, and rituximab regimen as a systemic therapy may represent an ideal choice for patients with hyperviscosity in Waldenström macroglobulinemia.

Indexed as

Retinal Vein OcclusionWaldenstrom MacroglobulinemiaAdultBortezomibHumansMaleBortezomibCRVOHyperviscosity syndromeLymphoplasmacytic lymphomaWaldenström macroglobulinemia

Identifiers

PMID36804919
PMCPMC9940326
OpenAlexW4321351043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.